Retrospective Study

Development and validation of a risk prediction score for the severity of acute hypertriglyceridemic pancreatitis in Chinese patients

Zi-Yu Liu, Lei Tian, Xiang-Yao Sun, Zong-Shi Liu, Li-Jie Hao, Wen-Wen Shen, Yan-Qiu Gao, Hui-Hong Zhai

Abstract

BACKGROUND
The frequency of acute hypertriglyceridemic pancreatitis (AHTGP) is increasing worldwide. AHTGP may be associated with a more severe clinical course and greater mortality than pancreatitis caused by other causes. Early identification of patients with severe inclination is essential for clinical decision-making and improving prognosis. Therefore, we first developed and validated a risk prediction score for the severity of AHTGP in Chinese patients.

AIM
To develop and validate a risk prediction score for the severity of AHTGP in Chinese patients.

METHODS
We performed a retrospective study including 243 patients with AHTGP. Patients were randomly divided into a development cohort (n = 170) and a validation cohort (n = 73). Least absolute shrinkage and selection operator and logistic regression were used to screen 42 potential predictive variables to construct a risk score for the severity of AHTGP. We evaluated the performance of the nomogram and compared it with existing scoring systems. Last, we used the best cutoff value...
(88.16) for severe acute pancreatitis (SAP) to determine the risk stratification classification.

RESULTS
Age, the reduction in apolipoprotein A1 and the presence of pleural effusion were independent risk factors for SAP and were used to construct the nomogram (risk prediction score referred to as AAP). The concordance index of the nomogram in the development and validation groups was 0.930 and 0.928, respectively. Calibration plots demonstrate excellent agreement between the predicted and actual probabilities in SAP patients. The area under the curve of the nomogram (0.929) was better than those of the Bedside Index of Severity in AP (BISAP), Ranson, Acute Physiology and Chronic Health Evaluation (APACHE II), modified computed tomography severity index (MCTSI), and early achievable severity index scores (0.852, 0.825, 0.807, 0.831 and 0.807, respectively). In comparison with these scores, the integrated discrimination improvement and decision curve analysis showed improved accuracy in predicting SAP and better net benefits for clinical decisions. Receiver operating characteristic curve analysis was used to determine risk stratification classification for AHTGP by dividing patients into high-risk and low-risk groups according to the best cutoff value (88.16). The high-risk group (> 88.16) was closely related to the appearance of local and systemic complications, Ranson score ≥ 3, BISAP score ≥ 3, MCTSI score ≥ 4, APACHE II score ≥ 8, C-reactive protein level ≥ 190, and length of hospital stay.

CONCLUSION
The nomogram could help identify AHTGP patients who are likely to develop SAP at an early stage, which is of great value in guiding clinical decisions.

Key Words: Nomogram; Severity; Acute pancreatitis; Prediction model

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: A risk prediction score (referred to as AAP), including age, the level of apolipoprotein A1 and the presence of pleural effusion, was first built to predict the severity of acute hypertriglyceridemic pancreatitis in Chinese patients. After calibration and verification, this score was shown to have high predictive accuracy and good performance. The risk score could help identify patients who are likely to develop severe acute pancreatitis at an early stage. In comparison with other scores, these scores showed improved accuracy in predicting and better net benefits for clinical decisions. AAP could be of great value in guiding clinical decisions as a convenient and specific tool.

Citation: Liu ZY, Tian L, Sun XY, Liu ZS, Hao LJ, Shen WW, Gao YQ, Zhai HH. Development and validation of a risk prediction score for the severity of acute hypertriglyceridemic pancreatitis in Chinese patients. World J Gastroenterol 2022; 28(33): 4846-4860
URL: https://www.wjgnet.com/1007-9327/full/v28/i33/4846.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i33.4846

INTRODUCTION
Hypertriglyceridemia (HTG) is the third most common cause of acute pancreatitis (AP)[1]. The frequency of acute hypertriglyceridemic pancreatitis (AHTGP) as a type of AP is increasing worldwide[2]. One multicenter study conducted in Beijing found that AHTGP was present in 10.36% of patients with AP[3,4]. Furthermore, some evidence suggests that AHTGP may be associated with a more severe clinical course and greater mortality than pancreatitis caused by other causes[1,5,6]. Patients with severe AP (SAP) characteristically have pancreatic necrosis or distant organ failure with a mortality rate of up to 40%[7]. Early identification of patients with severe inclination is essential for the delivery of specific interventions or intensive care support in a timely manner, as well as for improving prognosis. This indicates the importance of predicting the severity of AHTGP[8].

At present, four commonly used AP scoring systems are available for the early identification of SAP, including the Acute Physiology and Chronic Health Evaluation (APACHE II), Ranson score, the Bedside Index of Severity in AP (BISAP), and the modified computed tomography (CT) severity index (MCTSI). However, they have limitations[9]. APACHE II collects a large number of parameters, making it complicated and inconvenient to use and poor at predicting disease within 24 h of disease onset. The Ranson score consists of 11 indicators, which must be evaluated upon admission and 48 h following admission. Some of these indicators are not routinely collected during early stages of AP, so early
prediction is difficult[10]. BISAP uses five indicators to determine AP severity 24 h after admission. It is easy to use but has low sensitivity for predicting SAP[11]. The MCTSI has outstanding performance in predicting local complications. But it is poor in predicting severity[12]. The AP prediction accuracy could be improved by combining several scoring systems, but it was inconvenient. Without a new scoring system, it was difficult to increase the prediction accuracy[13].

Moreover, many studies have demonstrated that single laboratory indicators can be used to predict the severity of AHTGP, such as the neutrophil-lymphocyte ratio (NLR), white blood cell (WBC) count, red blood cell distribution width (RDW), serum calcium (Ca2+) and C-reactive protein (CRP), which are easy to use in practice but lack high sensitivity or specificity[2,14]. It should be noted that serum triglyceride (TG) levels dose-dependently worsen the outcome of AP[6], but there is still controversy[5]. Recently, several new clinical prediction models have been developed to predict the severity of AP[15,16]. The early achievable severity index (EASY) prediction score as an artificial intelligence model was recently developed based on machine learning for the early and easy prediction of severity in AP[17]. However, almost all of them were developed for all etiologies of pancreatitis and not for HTG-induced pancreatitis separately.

In conclusion, AHTGP may be associated with a more severe clinical course and greater mortality. Early prediction and detection of patients who are likely to develop SAP is of great importance. The purpose of this study is to develop and validate a fast, simple, accurate, and reproducible risk score for predicting severe AHTGP at an early stage.

**MATERIALS AND METHODS**

**Patient selection and data processing**
The study involved a retrospective review of 243 patients diagnosed with AHTGP who were admitted to the Intensive Care Unit of a gastroenterology department of Xuanwu Hospital from November 2012 to January 2022. All patients were diagnosed with AHTGP for the first time, and the possibility of other pancreatic diseases (recurrent AP, chronic pancreatitis, or pancreatic cancer) and cases with missing data were excluded. The following data were recorded: Basic demographics, medical history, vital signs, laboratory tests and X-ray of the chest within 24 h. Pancreatic examinations under CT or magnetic resonance imaging within 72 h. All patients received routine management after admission. This study was approved by the Ethics Committee of the Xuanwu Hospital of Capital Medical University; written informed consent was waived considering the retrospective study design.

**Diagnosis and scoring systems**
The diagnostic criteria for AHTGP were elevated TG level (> 11.30 mmol/L, or 5.65-11.30 mmol/L with lactescent serum) and two or more of the following three symptoms: (1) Abdominal pain consistent with AP; (2) Levels of amylase and/or lipase at least three times above the upper limit of normal; and (3) Abdominal imaging consistent with changes in AP. According to the Atlanta classification revised in 2012, AP severity was divided into three groups based on organ failure status and local and/or systemic complications. The absence of organ failure and local or systemic complications was considered to indicate mild AP (MAP). The presence of transient (within 48 h) organ failure and/or local complications or exacerbation of comorbid disease was regarded as moderately severe AP (MSAP). The presence of persistent (> 48 h) organ failure was considered to indicate SAP. The respiratory, cardiovascular, and renal systems were assessed to identify organ failure, which was defined as a modified Marshall score > 2 for one of these three systems. Acute peripancreatic fluid collection, pancreatic pseudocyst, acute necrotic collection, walled-off necrosis, and infected pancreatic necrosis were defined as local complications[18].

As part of the validation process, five scoring systems were compared to our risk prediction score. Within 24 h of admission, laboratory tests and radiological examinations were conducted to determine APACHE II and BISAP scores. The Ranson score was derived from laboratory tests performed within 48 h of admission. The MCTSI score was determined from CT scans performed within 72 h of admission. The EASY prediction score as an artificial intelligence model was recently developed to predict the severity of AP. It consists of four parts (personal details, anamnestic data, admission data and blood test results) with a total of 23 predictors. We calculated the predicted severity scores for all subjects on a web application (http://easy-app.org/) in the Streamlit Python-based framework.

**Potential predictive variables**
We selected 42 potential predictive variables based on the literature and previous clinical experience, including demographic variables, medical history, clinical signs, laboratory findings, and imaging results. Demographic variables included continuous and categorical variables: Age, body mass index (BMI), smoking status, and drinking habits. Medical history included categorical variables: Diabetes, hypertension, hyperlipemia, and fatty liver. Clinical signs included continuous variables: Respiratory rate (RR), heart rate (HR), systolic blood pressure, and diastolic blood pressure. Laboratory findings performed within 24 h of admission included WBC, NLR[14], RDW[19], platelet counts (PLT), mean
platelet volume (MPV) [20], platelet distribution width (PDW) [21], total cholesterol (TC) [22], TG [6], high-density lipoprotein cholesterol level to low-density lipoprotein cholesterol level ratio (H/L ratio) [23], apolipoprotein A1 (ApoA1) [24], total bilirubin (TBIL), aspartate transaminase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), albumin (ALB) [25], blood urea nitrogen (BUN) [24], serum creatinine (Cr) [26], free triiodothyronine (fT3) [27], CRP, procalcitonin (PCT), serum sodium (Na), serum potassium (K), serum Ca++, prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen (FIB) [28], and D-dimer levels [29]. Imaging results included the presence of a pleural effusion according to the chest X-ray within 24 h of admission [30].

Outcomes
We defined the severity of AHTGP according to the revised Atlanta classification given the extensive acceptance of this guideline [18]. SAP was defined as persistent organ failure and was used as the clinical outcome measure.

Statistical analysis
Statistical comparisons between the non-SAP (MAP + MSAP) and SAP groups were performed with analysis of variance or the Mann–Whitney U test for continuous variables and the chi-square test or Fisher’s exact test for categorical variables. There were 42 variables entered into the selection process, as described here. Least absolute shrinkage and selection operator (LASSO) regression was applied to minimize the potential collinearity of variables measured from the same patient and overfitting of variables. The most predictive covariates were selected by the minimum (λ) min. Subsequently, variables identified by LASSO regression analysis and some other important clinical variables were entered into univariable and multivariable logistic regression analyses for further predictor selection. Clinical patient samples were randomly divided (3:1) into development and validation cohorts. We constructed a nomogram and validated the accuracy estimates by using 1000 bootstrap resamples to reduce overfitting. To quantify the discrimination performance of the nomogram for predicting SAP, the concordance index (C-index) was measured in the development set and validation cohort. By plotting the calibration curve, we analyzed the relationship between the observed incidence and predicted probability in the development set and the validation set. Integrated discrimination improvement (IDI) was established to evaluate the improvement of the risk prediction score with other existing scoring systems in the whole set. Decision curve analysis (DCA) was applied to quantify the clinical usefulness of the nomogram in the whole set. All statistical analyses were performed by R software (https://www.r-project.org/, The R Foundation) and Empower-Stats software (http://www.empowerstats.com, X&Y Solutions, Inc., Boston, MA, United States).

Risk group
To determine the risk stratification classification for AHTGP, the best cutoff value for SAP calculated through the ROC curve was used to divide patients into high-risk and low-risk groups. The differences in clinical manifestations and prognoses between the high- and low-risk groups were also compared to evaluate the efficacy of our risk score.

RESULTS

Clinical characteristics
A total of 243 records from patients diagnosed with AHTGP and discharged from the intensive care units (ICUs) during our study period were included for analysis. The baseline characteristics of the study population are summarized in Table 1. The average age of the entire cohort was 40.12 ± 10.12 years, and there were more males (n = 188, 77.37%) than females (n = 55, 22.63%). We divided our AP patients into two groups, non-SAP (MAP + MSAP) and SAP. The total rate of SAP was 25.51%. There was no significant difference in age, sex or BMI between the two groups. Furthermore, there was no significant difference in medical history between the two groups. In terms of vital signs, patients with SAP had a significantly higher heart rate (92.23 ± 16.29 vs 74.19% , P < 0.001) and respiratory rate (20.47 ± 4.38 vs 25.27 ± 6.21, P < 0.001) index than patients in the non-SAP group. Patients in the two groups showed no significant difference in laboratory findings, including PLT, MPV, H/L ratio, TBIL, ALT, ALP, fT3, Na, K, and TT. However, there were differences in WBC, NLR, RDW, PDW, TC, TG, ApoA1, AST, ALB, BUN, Cr, CRP, PCT, ESR, Ca++, PT, APTT, FIB, and D-dimer. For imaging results, pleural effusions were significantly more frequently observed among SAP patients (12.71% vs 74.19%, P < 0.001).

Predictor selection
Forty-two variables measured at the hospital within 24 h of admission were included in the LASSO regression. After LASSO regression selection (Figure 1), with a lambda of 0.028, 10 variables remained significant predictors of SAP, including age, HR, RR, ApoA1, WBC, Bun, Cr, Ca++, D-dimer, and the
| Patient characteristics | All (n = 243) | Non-SAP (n = 181) | SAP (n = 62) | P value |
|-------------------------|--------------|------------------|-------------|---------|
| **Demographic variables** |              |                  |             |         |
| Sex, n (%)              |              |                  |             |         |
| Male                    | 188 (77.37)  | 143 (79.00)      | 45 (72.60)  | 0.297   |
| Female                  | 55 (22.63)   | 38 (21.00)       | 17 (27.40)  |         |
| Age (yr)                | 40.12 ± 10.12| 39.60 ± 10.10    | 41.60 ± 10.20| 0.190   |
| BMI (kg/m²)             | 28.27 ± 4.25 | 28.10 ± 4.00     | 28.70 ± 4.90| 0.367   |
| **Medical history**     |              |                  |             |         |
| Diabetes, n (%)         |              |                  |             |         |
| Yes                     | 139 (57.20)  | 102 (56.40)      | 37 (59.70)  | 0.648   |
| No                      | 104 (42.80)  | 79 (43.65)       | 25 (40.30)  |         |
| Hypertension, n (%)     |              |                  |             |         |
| Yes                     | 59 (24.28)   | 48 (26.50)       | 11 (17.70)  | 0.164   |
| No                      | 184 (75.72)  | 133 (73.50)      | 51 (82.30)  |         |
| Hyperlipidemia, n (%)   |              |                  |             |         |
| Yes                     | 152 (62.55)  | 64 (35.40)       | 27 (43.50)  | 0.250   |
| No                      | 91 (37.45)   | 64 (35.40)       | 27 (43.50)  |         |
| Fatty liver, n (%)      |              |                  |             |         |
| Yes                     | 185 (76.13)  | 143 (79.00)      | 42 (67.70)  | 0.073   |
| No                      | 58 (23.87)   | 38 (21.00)       | 20 (32.30)  |         |
| Drinking, n (%)         |              |                  |             |         |
| Yes                     | 120 (49.38)  | 87 (48.10)       | 33 (53.20)  | 0.483   |
| No                      | 123 (50.62)  | 94 (51.90)       | 29 (46.80)  |         |
| Smoking, n (%)          |              |                  |             |         |
| Yes                     | 133 (54.73)  | 102 (56.40)      | 31 (50.00)  | 0.386   |
| No                      | 110 (45.27)  | 79 (43.60)       | 31 (50.00)  |         |
| **Clinical signs**      |              |                  |             |         |
| HR (bpm)                | 96.14 ± 18.17| 92.23 ± 16.30    | 107.58 ± 18.65| < 0.001 |
| R (bpm)                 | 21.66 ± 5.33 | 20.47 ± 4.38     | 25.27 ± 6.21| < 0.001 |
| SBP (mmHg)              | 133.50 ± 17.52| 133.51 ± 16.56  | 133.48 ± 20.21| 0.992   |
| DBP (mmHg)              | 81.13 ± 12.03| 80.85 ± 11.28    | 81.92 ± 14.08| 0.548   |
| **Laboratory findings** |              |                  |             |         |
| WBC (× 10⁹/L)           | 12.53 ± 3.86 | 11.96 ± 3.63     | 14.41 ± 3.97| < 0.001 |
| NLR                     | 9.94 ± 7.27  | 8.82 ± 6.98      | 13.19 ± 7.15| < 0.001 |
| RDW (fL)                | 12.87 ± 0.72 | 12.80 ± 0.69     | 13.08 ± 0.78| 0.009   |
| PLT (× 10⁹/L)           | 218.91 ± 61.98| 216.09 ± 57.99  | 227.15 ± 72.30| 0.226   |
| MPV (fL)                | 10.75 ± 1.05 | 10.68 ± 1.01     | 10.95 ± 1.14| 0.074   |
| PDW (fL)                | 12.66 ± 2.22 | 12.47 ± 2.09     | 13.23 ± 2.47| 0.018   |
| TC (mmol/L)             | 10.15 ± 4.11 | 9.54 ± 3.62      | 11.94 ± 4.92| < 0.001 |
| TG (mmol/L)             | 21.08 ± 7.50 | 20.17 ± 7.31     | 23.75 ± 7.49| 0.001   |
| H/L ratio               | 0.96 ± 1.36  | 0.96 ± 1.36      | 0.97 ± 1.36 | 0.946   |

Non-SAP (n = 181, 74.49%)  SAP (n = 62, 25.51%)
ApoA1 (g/L) | 1.02 ± 0.35 | 1.11 ± 0.34 | 0.75 ± 0.23 | < 0.001
TBIL (μmol/L) | 14.16 ± 8.29 | 13.81 ± 7.11 | 15.16 ± 11.03 | 0.987
AST (U/L) | 29.78 ± 17.41 | 27.40 ± 13.03 | 36.76 ± 25.20 | < 0.001
ALT (U/L) | 31.04 ± 28.70 | 30.80 ± 29.94 | 31.73 ± 24.94 | 0.826
ALP (U/L) | 73.91 ± 25.30 | 73.59 ± 22.70 | 74.84 ± 31.88 | 0.737
ALB (g/L) | 41.57 ± 5.91 | 42.22 ± 5.53 | 39.66 ± 6.58 | 0.003
BUN mmol/L | 4.32 ± 2.03 | 4.05 ± 1.39 | 5.10 ± 3.12 | < 0.001
Cr (μmol/L) | 62.62 ± 42.98 | 56.64 ± 15.83 | 80.10 ± 78.56 | < 0.001
fT3 (pmol/L) | 1.97 ± 0.37 | 1.99 ± 0.36 | 1.91 ± 0.41 | 0.134
CRP (mg/L) | 160.20 ± 127.36 | 133.55 ± 112.64 | 237.99 ± 136.59 | < 0.001
PCT (ng/mL) | 0.80 ± 1.93 | 0.59 ± 1.72 | 1.42 ± 2.35 | 0.003
ESR (mm/h) | 42.57 ± 24.76 | 40.71 ± 25.10 | 47.99 ± 23.06 | 0.045
Na (mmol/L) | 133.97 ± 4.29 | 134.28 ± 4.09 | 133.07 ± 4.76 | 0.054
K (mmol/L) | 4.02 ± 0.46 | 3.97 ± 0.35 | 4.19 ± 0.67 | 0.080
Ca²⁺ (mmol/L) | 2.13 ± 0.26 | 2.19 ± 0.18 | 1.96 ± 0.36 | < 0.001
PT (s) | 13.26 ± 0.98 | 13.12 ± 0.84 | 13.68 ± 1.21 | < 0.001
APTT (s) | 37.82 ± 5.28 | 37.35 ± 5.14 | 39.22 ± 5.45 | 0.016
TT (s) | 15.07 ± 1.10 | 15.08 ± 1.09 | 15.05 ± 1.13 | 0.823
FIB (g/L) | 5.70 ± 2.21 | 5.41 ± 2.10 | 6.56 ± 2.32 | < 0.001
D-dimer (μg/L) | 1.34 ± 1.83 | 0.94 ± 0.98 | 2.51 ± 2.94 | < 0.001

**Imaging results**

| Pleural effusion, n (%) | < 0.001 |
|------------------------|--------|
| Yes                    | 69 (28.40) | 23 (12.71) | 46 (74.19) |
| No                     | 174 (71.61) | 158 (87.30) | 16 (25.81) |

**BMI**: Body mass index; **RR**: Respiratory rate; **HR**: Heart rate; **SBP**: Systolic blood pressure; **DBP**: Diastolic blood pressure; **SAP**: Severe acute pancreatitis; **Non-SAP**: Mild acute pancreatitis and moderately severe acute pancreatitis; **WBC**: White blood cell; **NLR**: Neutrophil to lymphocyte ratio; **RDW**: Red blood cell distribution width; **PLT**: Platelet counts; **RDW**: MPV Mean platelet volume; **PDW**: Platelet distribution width; **TC**: Total cholesterol; **TG**: Triglyceride; **HDL-C**: High-density lipoprotein cholesterol; **LDL-C**: Low-density lipoprotein cholesterol; **ApoA1**: Apolipoprotein A1; **TBIL**: Total bilirubin; **AST**: Aspartate transaminase; **ALT**: Alanine aminotransferase; **ALP**: Alkaline phosphatase; **ALB**: Albumin; **BUN**: Blood urea nitrogen; **Cr**: Creatinine; **fT3**: Free triiodothyronine; **CRP**: C-reactive protein; **PCT**: Procalcitonin; **Na**: Sodium; **K**: Potassium; **Ca²⁺**: Calcium; **PT**: Prothrombin time; **APTT**: Activated partial thromboplastin time; **TT**: Thrombin time; **FIB**: Fibrinogen; **SAP**: Severe acute pancreatitis; **Non-SAP**: Mild acute pancreatitis and moderately severe acute pancreatitis.

The presence of pleural effusion. According to a previous study, TG levels dose-dependently increase the severity of AP [6]. The presence of metabolic syndrome and its components associated with increasing AP severity were also important factors [31, 32]. Therefore, we included TG level, BMI, history of hypertension and diabetes in the regression analysis. Based on the Endocrine SocietyClinical Practice Guideline and previously published study, we divided TG levels into three groups as classified by variables (group 1: < 11.3 mmol/L; group 2: 11.3-22.59 mmol/L; group 3: ≥ 22.6 mmol/L) for clinical use [6].

**Univariable and multivariable logistic regression**

Inclusion of these 14 variables in a logistic regression model resulted in four variables that were independently statistically significant predictors of SAP (Table 2): Age (OR: 1.07; 95% CI: 1.01-1.14; P = 0.033), ApoA1 (OR: 0.02; 95% CI: 0.00-0.12; P < 0.0001), Ca²⁺ (OR: 0.11; 95% CI: 0.01-0.90; P = 0.040) and the presence of pleural effusion (OR: 15.61; 95% CI: 5.05-48.24; P < 0.0001).

**Construction and validation of the nomogram**

Clinical patient samples were randomly divided (3:1) into development and validation cohorts. Due to the small sample size, we used 1000 bootstrap resamples for development and validation to reduce over-the-fit bias. The multivariable analyses demonstrated that age, the reduction in ApoA1 and Ca²⁺, and the presence of pleural effusion were independent risk factors for SAP. Considering that the level of...
Table 2 Univariable and multivariable logistic regression analyses of predictive factors for severe acute pancreatitis in all subjects

| Variables          | Univariable regression | Multivariable regression |
|--------------------|------------------------|--------------------------|
|                    | OR (95%CI)             | P value                  | OR (95%CI)             | P value |
| Age                | 1.02 (0.99-1.05)       | 0.190                    | 1.07 (1.01-1.14)       | 0.033   |
| BMI (kg/m²)        | 1.03 (0.96-1.10)       | 0.566                    | 1.08 (0.94-1.24)       | 0.278   |
| Hypertension       |                        |                          |                         |         |
| No                 | 1.00                   |                          | 1.00                   |         |
| Yes                | 0.60 (0.29-1.24)       | 0.167                    | 1.02 (0.99-1.06)       | 0.201   |
| Diabetes           |                        |                          |                         |         |
| No                 | 1.00                   |                          | 1.00                   |         |
| Yes                | 1.15 (0.64-2.06)       | 0.648                    | 1.27 (0.38-4.24)       | 0.693   |
| HR (bpm)           | 1.05 (1.03-1.07)       | < 0.0001                 | 1.02 (0.99-1.06)       | 0.201   |
| RR (bpm)           | 1.20 (1.12-1.29)       | < 0.0001                 | 1.12 (0.99-1.26)       | 0.068   |
| TG (mmol/L)        |                        |                          |                         |         |
| < 11.3             | 1.00                   |                          | 1.00                   |         |
| 11.3-22.6          | 2.06 (0.57-7.49)       | 0.273                    | 4.20 (0.40-44.25)      | 0.232   |
| ≥ 22.6             | 3.43 (0.96-12.20)      | 0.057                    | 5.95 (0.56-62.75)      | 0.138   |
| ApoA1 (g/L)        | 0.01 (0.00-0.05)       | < 0.0001                 | 0.02 (0.00-0.12)       | < 0.0001|
| Cr (μmol/L)        | 1.02 (1.01-1.03)       | 0.002                    | 1.01 (0.99-1.02)       | 0.458   |
| Bun (μmol/L)       | 1.27 (1.10-1.48)       | 0.001                    | 1.29 (0.92-1.81)       | 0.145   |
| WBC (×10⁹/L)       | 1.18 (1.09-1.28)       | < 0.0001                 | 1.08 (0.95-1.24)       | 0.248   |
| Ca²⁺ (mmol/L)      | 0.02 (0.01-0.09)       | < 0.0001                 | 0.11 (0.01-0.12)       | 0.040   |
| D-dimer (μg/L)     | 1.69 (1.35-2.12)       | < 0.0001                 | 1.24 (0.94-1.63)       | 0.122   |
| Pleural effusion   | 19.75 (9.64-40.48)     | < 0.0001                 | 15.62 (5.05-48.24)     | < 0.0001|

BMI: Body mass index; RR: Respiratory rate; HR: Heart rate; SBP: Systolic blood pressure; WBC: White blood cell; ApoA1: Apolipoprotein A1; BUN: Blood urea nitrogen; Cr: Creatinine; Ca: Calcium; SAP: Severe acute pancreatitis; OR: Odds ratio.

TG, BMI and history of hypertension and diabetes may also be important predictors, we constructed three predictive models based on different combinations of these factors. The logistic regression function was as follows: Model 1 (including age, ApoA1, and pleural effusion): \[ \log (\text{odds of SAP}) = -0.15 \times \text{(constant)} + 0.06 \times \text{age} - 5.49 \times \text{ApoA1} + 3.57 \times \text{(pleural effusion = 1)}; \]
Model 2 (including age, ApoA1, Ca²⁺ and pleural effusion): \[ \log (\text{odds of SAP}) = 4.86 \times \text{(constant)} + 0.06 \times \text{age} - 5.32 \times \text{ApoA1} - 2.40 \times \text{Ca²⁺} + 3.31 \times \text{(pleural effusion = 1)}; \]
Model 3 (including age, diabetes, hypertension, BMI, TG, ApoA1 and pleural effusion): \[ \log (\text{odds of SAP}) = 7.30 \times \text{(constant)} + 0.15 \times \text{age} - 0.15 \times \text{BMI} - 0.35 \times \text{(hypertension = 1)} - 0.09 \times \text{(diabetes = 1)} - 6.72 \times \text{ApoA1} + 3.98 \times \text{(pleural effusion = 1)} + 3.39 \times \text{(TG = 1)} + 3.23 \times \text{(TG = 2)}. \]
ROC curve analysis was applied to evaluate the diagnostic performance of the three predictive models (Supplementary Figure 1). Model 1 had no significant differences in receiver operating characteristic curves (AUCs) and IDI between Model 2 and Model 3 (Supplementary Table 1).

For clinical convenience and easy application, we selected Model 1 with the fewest factors as the final risk prediction score and constructed the nomogram (referred to as AAP) (Figure 2). The C-index for the development and validation cohorts after bootstrapping were 0.930 (95%CI: 0.893-0.967) and 0.928 (95%CI: 0.867-0.990), respectively (Figure 3A and B). This suggested a nomogram with good discrimination. The calibration curve of the nomogram is presented in Figure 3C and D. Calibration plots fall on a 45-degree diagonal line, which shows good agreement between the predicted and actual probabilities in SAP patients in the development and validation cohorts.

Clinical use
An ROC curve analysis was applied to evaluate the diagnostic efficacy of the new risk prediction score (referred to as AAP) and other clinical scoring systems, including the BISAP, Ranson, APACHE II, MCTSI and EASY. The AUC values of AAP, BISAP, RASON, APACHE II, MCTSI and EASY to predict SAP were 0.929 (95%CI: 0.889-0.958), 0.852 (95%CI: 0.801-0.894), 0.825 (95%CI: 0.771-0.871), 0.807
Figure 1 Feature selection using the least absolute shrinkage and selection operator binary logistic regression model. A: Least absolute shrinkage and selection operator (LASSO) coefficient profiles of the 42 baseline features; B: Tuning parameter (λ) selection in the LASSO model using 10-fold cross-validation via minimum criteria.

Figure 2 Nomogram for predicting severe acute pancreatitis for patients in the development cohort. SAP: Severe acute pancreatitis.

AAP achieved the highest AUC in predicting SAP among the scoring systems (Table 3). The improvement in the prediction of SAP was evaluated by calculating the IDI. IDIs were employed to compare the discriminative ability between the new model and the other clinical scoring systems. These results demonstrated that our nomogram has a greater potential for accurately predicting SAP than the other four clinical scoring systems (Table 4).

DCA was used to compare the clinical usability and benefits of the nomogram throughout the whole cohort. DCA plots showed that our nomogram had greater net benefits than other system scores for predicting the severity of AP patients, which demonstrated its utility in clinical decision-making (Figure 5).

Risk stratification based on the Nomogram for SAP
To determine the risk stratification classification for AP, the best cutoff value (88.16) for SAP calculated through the ROC curve was used to divide patients into high-risk and low-risk groups. We further analyzed the relationship between the AAP cutoff value (88.16) and clinical parameters. The high-risk group was closely related to local and system complications: Ranson ≥ 3, BISAP ≥ 3, MCTSI ≥ 4, APACHE-II ≥ 8, CRP ≥ 190, and the length of hospital stay (Table 5).
Table 3 Comparison of diagnostic performance for predicting severe acute pancreatitis between the AAP and other existing clinical scores

| Variables       | Δ AUC  | 95%CI     | Z statistic | P value |
|-----------------|--------|-----------|-------------|---------|
| AAP-APACHE II   | 0.122  | 0.057-0.187 | 3.661       | 0.000   |
| AAP-BISAP       | 0.076  | 0.007-0.198 | 3.839       | 0.000   |
| AAP-MCTSI       | 0.098  | 0.027-0.305 | 3.111       | 0.002   |
| AAP-Ranson      | 0.104  | 0.048-0.159 | 3.670       | 0.000   |
| AAP-EASY        | 0.122  | 0.056-0.188 | 3.606       | 0.000   |

AAP: Our risk prediction score referred to as AAP; EASY: EASY prediction score; Δ AUC: Difference of areas under curve between AAP and other clinical scores; SE: Standard error; CI: Confidence interval; SAP: Severe acute pancreatitis.

Table 4 Diagnostic performance of the integrated discrimination improvement between the AAP and other clinical scores

| Variables       | IDI   | SE    | 95%CI     | Z statistic | P value |
|-----------------|-------|-------|-----------|-------------|---------|
| AAP-APACHE-II   | 0.201 | 0.077 | 0.050-0.352 | 2.601       | 0.009   |
| AAP-BISAP       | 0.095 | 0.052 | 0.037-0.115 | 1.828       | 0.068   |
| AAP-MCTSI       | 0.166 | 0.071 | 0.036-0.160 | 2.339       | 0.019   |
| AAP-Ranson      | 0.216 | 0.063 | 0.093-0.338 | 3.444       | 0.001   |
| AAP-EASY        | 0.205 | 0.082 | 0.045-0.365 | 2.513       | 0.012   |

IDI: Integrated discrimination improvement; SE: Standard error; CI: Confidence interval; AAP: Our risk prediction score referred to as AAP; EASY: EASY prediction score; SAP: Severe acute pancreatitis.

**DISCUSSION**

AHTGP has grown in incidence and importance. According to the previously published literature, HTG is the third most common cause of AP\(^6\). Clinically, AHTGP is similar to other forms of AP, but it is associated with significantly higher complication rates, severity, and mortality\(^5,6\). Thus, recognizing risk factors for severe AHTGP in the early stages is very important for triaging patients appropriately to ICUs and providing specific treatments. In the present study, we developed a convenient and specific nomogram based on three predictors for predicting the severity of patients with AHTGP. The nomogram showed great calibration and discriminatory abilities in both the development and validation groups. In addition, our nomogram has shown improved prognostic reliability, accuracy and the best net benefit when compared to other clinical scoring systems, such as BISAP, Ranson, APACHE II, CTSI and an artificial intelligence model, the EASY prediction score. Moreover, the model could distinguish patients into low-risk and high-risk groups according to the best cutoff point (88.16). Patients with higher scores had a higher probability of developing SAP than those with lower scores. The cutoff point can help doctors in making medical decisions.

As mentioned in the introduction, four commonly used AP scoring systems, including APACHE II, Ranson, BISAP, and MCTSI, have limitations on their abilities to identify SAP early. According to our results, our prediction score AAP has three easily available parameters lower than other scoring systems, which is easy for clinical application. Meanwhile, it has better performance in diagnostic efficacy and clinical decision-making for patients with AHTGP. It is worth mentioning that an artificial intelligence model-EASY prediction score consisting of 23 parameters was developed recently based on a multicenter, multinational, prospective and observational study\(^17\). We applied this model to our research population. Although it achieved a high AUC in predicting SAP, it was still the lowest among the AAP and four commonly used AP scoring systems. This may suggest that the prediction ability of the EASY model is limited for pancreatitis caused by HTG.

Notably, we introduced a new predictor, ApoA1, into our risk score compared with other clinical scoring systems. Recent studies have shown a negative correlation between ApoA1 and the severity of AP, and decreased serum levels of ApoA1 have been linked to the occurrence of SAP in patients\(^23,30\). The mechanism can be explained as follows: In SAP patients, excessive inflammatory cytokines inhibit synthesis. Recent studies showed a negative correlation between ApoA1 and the severity of AP, and decreased serum levels of ApoA1 have been linked to the occurrence of SAP in patients and lead to lipoprotein degradation\(^34\). Our previous study showed that the best cutoff point of ApoA1 for
Table 5 The relationship between risk stratification and clinical parameters

| Local complications | Low-risk group (n = 158) | High-risk group (n = 85) | P value |
|---------------------|--------------------------|--------------------------|---------|
| APFC                | 43 (27.22%)              | 68 (80.00%)              | < 0.001 |
| PPC                 | 3 (1.90%)                | 10 (11.77%)              | 0.001   |
| ANC                 | 3 (1.90%)                | 22 (25.88%)              | < 0.001 |
| WON                 | 0 (0.00%)                | 4 (4.71%)                | 0.014   |
| Systemic complications |                         |                          |         |
| SIRS                | 92 (58.23%)              | 72 (84.71%)              | < 0.001 |
| Respiratory failure | 29 (18.35%)              | 59 (69.41%)              | < 0.001 |
| Renal failure       | 0 (0.00%)                | 13 (15.29%)              | < 0.001 |
| Cardiovascular failure | 2 (1.27%)            | 5 (5.88%)                | 0.040   |
| Clinical Scoring Systems |                     |                          |         |
| Ranson ≥ 3          | 28 (17.72%)              | 53 (62.35%)              | < 0.001 |
| BISAP ≥ 3           | 0 (0.00%)                | 4 (4.71%)                | 0.014   |
| MCTSI ≥ 4           | 15 (9.49%)               | 53 (62.35%)              | < 0.001 |
| APACHE-II ≥ 8       | 73 (46.20%)              | 68 (80.00%)              | < 0.001 |
| CRP ≥ 190           | 42 (26.58%)              | 44 (51.77%)              | < 0.001 |
| Hospital day, days  | 13.51 ± 5.45             | 20.04 ± 8.14             | < 0.001 |

APFC: Acute peripancreatic fluid collection; PPC: Pancreatic pseudocyst; ANC: Acute necrotic collection; WON: Walled-off necrosis; IPN: Infected pancreatic necrosis; SIRS: Systemic inflammatory response syndrome.

predicting severe acute hyperlipidemic pancreatitis was 0.8 g/L, whose sensitivity, specificity and Youden index were 0.877, 0.674 and 0.55, respectively[35]. Another study performed by Li et al[33] showed that ApoA1 predicts the optimal critical value of SAP to be 0.8 g/L, whose sensitivity, specificity and Youden index were 0.551, 0.757 and 0.693, respectively[33]. Therefore, ApoA1 has been found to be a reliable and validated indicator of SAP. Therefore, ApoA1 included in our model could increase the specificity and sensitivity of the nomogram.

Pleural effusion is one of the most common thoracic complications in AP patients. According to recent studies, the prevalence ranges from 46.0% to 72.3%[36]. The disruption of the pancreatic duct may result in leakage of pancreatic secretions directly into the peritoneal cavity via the transdiaphragmatic lymphatic channels[37]. According to the up-to-date revised Atlanta criteria, pleural effusion is a strong individual predictor of SAP. Additionally, pleural effusion is a valuable indicator of BISAP score. Yan et al[30] showed that on the basis of PEV, the AUC of 0.816 for predicting severe AP, with a threshold of 69.00 mL, and the sensitivity and specificity were 84.23% and 81.07, respectively. According to this study, pleural effusion volume can serve as a clinical biomarker to predict the severity and outcome of AP[30].

The evidence indicates that patients with HTG present a more severe form of pancreatitis. A previous study confirmed that HTG dose-dependently increases the complications and severity of AP[6]. However, a meta-analysis including 11965 patients from 16 eligible studies found no significant difference in AP severity based on the extent of HTG[5]. This study also explored the association between HTG levels and the severity of AHTGP. Compared to patients with TGs lower than 11.3 mmol/L, we found that patients with TGs above 22.6 mmol/L had a higher OR (OR: 5.95; 95%CI: 0.56-62.75; P = 0.232) than patients with TGs between 11.3 and 22.59 mmol/L (OR: 4.20; 95%CI: 0.40-44.25; P = 0.138). We speculated that there was a trend for HTG to dose-dependently increase the severity of AHTGP. Previous studies showed that the presence of metabolic syndrome and its components, including obesity, diabetes and hypertension, were significantly associated with increasing AP severity [31,32]. Our study showed that there was a trend that the presence of obesity (OR: 1.08; 95%CI: 0.94-1.24; P = 0.278), diabetes (OR: 1.27; 95%CI: 0.38-4.24; P = 0.693) and hypertension (OR: 1.02; 95%CI: 0.99-1.06; P = 0.201) increased the risk of SAP. However, the P values were not significant, probably because of our small sample size. The small sample size of our study makes it difficult to make extensive recommendations. The next step is to conduct a multicenter prospective cohort study with a large sample size to further explore this important issue.
The novelties and strengths of our study include the following: To the best of our knowledge, this is the first study attempting to develop a risk prediction score for HTG-induced pancreatitis. We also compared the risk prediction score with existing scoring systems in a sample of Chinese patients for predicting the severity of AHTGP. Although the established and validated nomogram in our study may provide a convenient and specific tool to assist physicians in clinical decisions, there are some limitations to be taken into account. First, this study was retrospective, so selection and detection bias could exist. Second, it was a single-center study with a small sample size, which lacked multicenter data verification. There is a need to externally validate the risk score prior to clinical use. Furthermore, the data used to develop and validate the score are all from China, which limits their generalizability to other parts of the world.

CONCLUSION

In this study, we developed a risk score to estimate the prediction of developing SAP among patients with AHTGP based on three variables commonly measured on admission to the hospital. Estimating the risk score could help identify patients who are likely to develop SAP at an early stage. It could be of great value in guiding clinical decisions as a convenient and specific tool and optimizing the use of medical resources by supporting appropriate treatment.

Figure 3 Receiver operating characteristic curves and calibration curves of the nomogram for predicting severe acute pancreatitis. A: Receiver operating characteristic curves (AUCs) in the development group; B: AUC in the validation group; C: Calibrations of the nomogram for predicting severe acute pancreatitis (SAP) in the development group; D: Calibrations of the nomogram for predicting SAP in the validation group.
Figure 4 Receiver operating characteristic curves for the AAP and other existing clinical scoring systems, such as Bedside Index of Severity in acute pancreatitis, Ranson, Acute Physiology and Chronic Health Evaluation II), modified computed tomography severity index and early achievable severity index prediction scores. AAP: Our risk prediction score referred to as AAP; EASY: The EASY prediction score is an artificial intelligence model for predicting the severity of acute pancreatitis.

Figure 5 Decision curve analysis for the nomogram. AAP: Our risk prediction score referred to as AAP; EASY: The EASY prediction score is an artificial intelligence model for predicting the severity of acute pancreatitis.

ARTICLE HIGHLIGHTS

Research background
The frequency of acute hypertriglyceridemic pancreatitis (AHTGP) is increasing worldwide. AHTGP may be associated with a more severe clinical course and greater mortality than pancreatitis caused by other causes. Early identification of patients with severe inclination is essential for clinical decision-making and improving prognosis. Hence, constructing a risk prediction score with high predictive accuracy and clinical utility for assessing the severity of AHTGP patients is of great importance.

Research motivation
Early prediction and detection of AHTGP patients who are likely to develop severe acute pancreatitis (SAP) is of great importance. Almost of existing clinical scores were developed for all etiologies of pancreatitis and not for hypertriglyceridemia (HTG)-induced pancreatitis separately. To the best of our knowledge, this is the first study attempting to develop a risk prediction score for HTG-induced pancreatitis. This risk score may help guide clinical decisions for these patients.
Research objectives
The purpose of this study was to establish a risk prediction score with easy use and high performance for predicting the severity of AHTGP patients in China, which will help doctors make rational clinical decisions.

Research methods
We performed a retrospective study of patients with AHTGP. Least absolute shrinkage and selection operator and logistic regression were used to screen predictive variables to construct a nomogram for predicting the severity of AHTGP. The predictive accuracy of the nomogram was estimated using the concordance index. The performance of the nomogram was estimated using a calibration curve. We evaluated the predictive accuracy and net benefit of the risk score and compared it with existing scoring systems via receiver operating characteristic curve analysis and decision curve analysis. We used the best cutoff value for SAP to determine the risk stratification classification.

Research results
A risk prediction score consisting of three predictors commonly measured on admission was constructed to predict the severity of SAP. More importantly, our nomogram exhibited high predictive accuracy and good performance. In addition, our nomogram has shown improved prognostic reliability, accuracy and the best net benefit when compared to other clinical scoring systems, such as Bedside Index of Severity in AP, Ranson, Acute Physiology and Chronic Health Evaluation II, modified computed tomography severity index and an artificial intelligence model, the early achievable severity index prediction score. Moreover, the risk prediction score could distinguish patients into low-risk and high-risk groups according to the best cutoff point. The cutoff point can help doctors in making medical decisions.

Research conclusions
This risk prediction score have potential usefulness in predicting the presence of SAP at an early stage. It could be of great value in guiding clinical decisions as a convenient and specific tool and optimizing the use of medical resources by supporting appropriate treatment.

Research perspectives
To the best of our knowledge, this is the first study attempting to develop a risk prediction score for HTG-induced pancreatitis. But, this was a single-center study with a small sample size, which lacked multi-center data verification. The next step is to conduct a multicenter prospective cohort study with a large sample size to construct specific risk score and externally validate the risk score prior to clinical use.

ACKNOWLEDGEMENTS
The authors express special thanks to Gui-Qi Zhu (Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, China) for his advice on data analysis.

FOOTNOTES
Author contributions: Liu ZY and Zhai HH designed the current study as the principal investigators; Liu ZY and Tian L. were involved in the study conception and design; Hao LJ, Shen WW and Gao YQ collected data; Liu ZY, Sun XY and Liu ZS drafted the plans for the data analyses, conducted statistical analyses and interpreted the data; Liu ZY drafted the manuscript; Tian L was responsible for language editing; All authors were involved in interpretation of the results and revision of the manuscript, and all approved the final version of the manuscript, the corresponding author attests that all the listed authors meet the authorship criteria and that no others meeting the criteria have been omitted.

Supported by 2021 National Natural Youth Cultivation Project of Xuanwu Hospital of Capital Medical University, No. QNPY2021018.

Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the Xuanwu Hospital of Capital Medical University, No. 2022102.

Informed consent statement: Written informed consent was waived considering the retrospective study design.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Data sharing statement: The clinical data was available from the corresponding author at zhaihuihong@263.net. And
no additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Country/Territory of origin:** China

**ORCID number:** Zi-Yu Liu 0000-0002-4095-3346; Lei Tian 0000-0002-5609-0098; Xiang-Yao Sun 0000-0001-9385-2402; Zong-Shi Liu 0000-0003-2431-8374; Li-Jie Hao 0000-0002-9130-9542; Wen-Wen Shen 0000-0002-2495-3530; Yan-Qiu Gao 0000-0001-7670-2381; Hui-Hong Zhai 0000-0002-8452-6311.

**S-Editor:** Fan JR

**L-Editor:** A

**P-Editor:** Fan JR

**REFERENCES**

1. **Hassanloo J**, Béland-Bonenfant S, Paquette M, Baass A, Bernard S. Prevalence, severity and management of hypertriglyceridemia-associated pancreatitis: A 7-year retrospective cohort study at canadian quaternary care hospitals. *J Clin Lipidol* 2022; [PMID: 35659855] DOI: 10.1016/j.jcl.2022.05.064

2. **Sun YM**, Gao F, Chen X, Zhang J. The relationship between triglyceride level and the severity of acute hypertriglyceridemic pancreatitis in Chinese patients. *Turk J Gastroenterol* 2020; 31: 633-639 [PMID: 33090100] DOI: 10.5152/tjg.2020.18353

3. **Zheng Y**, Zhou Z, Li H, Li J, Li A, Ma B, Zhang T, Liao Q, Ye Y, Zhang Z, Yang Y, Wang Z, Yang J, Li F. A multicenter study on etiology of acute pancreatitis in Beijing during 5 years. *Pancreas* 2015; 44: 409-414 [PMID: 25438072] DOI: 10.1097/MPA.0000000000000273

4. **Tai WP**, Lin XC, Liu H, Wang CH, Wu J, Zhang NW, Chen W. A Retrospective Research of the Characteristic of Hypertriglyceridemic Pancreatitis in Beijing, China. *Gastroenterol Res Pract* 2016; [PMID: 2663095] DOI: 10.1155/2016/2663095

5. **Kiss L**, Für G, Mátrai P, Hegyi P, Ivány E, Cazacu IM, Szabó I, Habon T, Alizadeh H, Gyoongyi Z, Vigh É, Eröss B, Erős A, Ottolfy M, Czakó L, Rakonczay Z Jr. The effect of serum triglyceride concentration on the outcome of acute pancreatitis: systematic review and meta-analysis. *Sci Rep* 2018; 8: 14096 [PMID: 30237456] DOI: 10.1038/s41598-018-3237-3

6. **Moszhacker D**, Hanák L, Forkas N, Szentesi A, Mikkó A, Bajor J, Sarlós P, Czinner J, Vincze Á, Hegyi PJ, Eröss B, Takács T, Czakó L, Németh BC, Izbéki F, Halász A, Gajdán L, Hamvas J, Béland-Bonenfant S, Paquette M, Baass A, Bernard S. Prevalence, severity and management of hypertriglyceridemia-associated pancreatitis: A 7-year retrospective cohort study at canadian quaternary care hospitals. *J Clin Lipidol* 2022; [PMID: 35659855] DOI: 10.1016/j.jcl.2022.05.064

7. **Hassanloo J**, Béland-Bonenfant S, Paquette M, Baass A, Bernard S. Prevalence, severity and management of hypertriglyceridemia-associated pancreatitis: A 7-year retrospective cohort study at canadian quaternary care hospitals. *J Clin Lipidol* 2022; [PMID: 35659855] DOI: 10.1016/j.jcl.2022.05.064

8. **de Pretis N**, Amadio A, Frulloni L. Hypertriglyceridemic pancreatitis: Epidemiology, pathophysiology and clinical management. *United European Gastroenterol J* 2018; 6: 649-655 [PMID: 30083325] DOI: 10.1177/2050640618755002

9. **Cho JH**, Kim TN, Chung IH, Kim KH. Comparison of scoring systems in predicting the severity of acute pancreatitis. *World J Gastroenterol* 2015; 21: 2387-2394 [PMID: 25741146] DOI: 10.3748/wjg.v21.i8.2387

10. **Wang L**, Zeng YB, Chen JY, Luo Q, Wang R, Zhang Z, Zheng D, Dong YH, Li ZS. A simple scoring system for predicting the mortality of severe acute pancreatitis: A retrospective clinical study. *Medicine (Baltimore)* 2020; 99: e20646 [PMID: 32502051] DOI: 10.1097/MD.00000000000020646

11. **Yang YX**, Li L. Evaluating the Ability of the Bedside Index for Severity of Acute Pancreatitis Score to Predict Severe Acute Pancreatitis: A Meta-Analysis. *Med Princ Pract* 2016; 25: 137-142 [PMID: 26613249] DOI: 10.1159/000441003

12. **Yang L**, Liu J, Xing Y, Du L, Chen J, Liu X, Hao J. Comparison of BISAP, Ranson, MCTSI, and APACHE II in Predicting Severity and Prognoses of Hyperlipidemic Acute Pancreatitis in Chinese Patients. *Gastroenterol Res Pract* 2016; 2016: 1834256 [PMID: 27882045] DOI: 10.1155/2016/1834256

13. **Mounzer R**, Langmead CJ, Wu BU, Evans AC, Bishehsari F, Muddana V, Singh VK, Silvka A, Whitcomb DC, Yadav D, Banks PA, Papachristou GI. Comparison of existing clinical scoring systems to predict persistent organ failure in patients with acute pancreatitis. *Gastroenterology* 2012; 142: 1476-82; quiz e15 [PMID: 22425589] DOI: 10.1053/j.gastro.2012.03.005

14. **Huang L**, Chen C, Yang L, Wan R, Hu G. Neutrophil-to-lymphocyte ratio can specifically predict the severity of hypertriglyceridemia-induced acute pancreatitis compared with white blood cell. *J Clin Lab Anal* 2019; 33: e22839 [PMID: 30737845] DOI: 10.1002/jcla.22839

15. **Hong W**, Lillenmo KD, Pan S, Zimmer V, Kontopantelis E, Stock S, Zippi M, Wang C, Zhou M. Development and
